SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
Current Report Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of Report: December 13, 2005
Corgenix Medical Corporation
(Exact Name of registrant as specified in its charter)
Nevada 000-24541 93-1223466
(State or other ommission File Number) I.R.S. Employer
jurisdiction Identification No.)
of incorporation) C
12061 Tejon Street
Westminster, Colorado 80234
(Address, including zip code, of principal executive offices)
(303) 457-4345 (Registrant's telephone number
including area code)
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:
- Written communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425)
-Soliciting Material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
-Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
-Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
ITEM 7.01 Regulation FD Disclosure
On December 14, 2005, Corgenix Medical Corporation management will meet
with shareholders at its annual shareholders meeting. A copy of the presentation
materials of the company's President and Chief Executive Officer to be were used
at that meeting is filed as Exhibit 99.1 hereto.
ITEM 9.01 Financial Statements and Exhibits
a) Not applicable.
b) Not applicable.
c) Exhibits:
99.1 Shareholder presentation material of the President and Chief
Executive Officer of Corgenix Medical Corporation used on December 14, 2005.
Safe Harbor Statement
Statements in this report that are not strictly historical facts are "forward
looking" statements (identified by the words "believe", "estimate", "project",
"expect" or similar expressions) within the meaning of the Private Securities
Litigation Reform Act of 1995. These statements inherently involve risks and
uncertainties that could cause actual results to differ materially from the
forward-looking statements. Factors that would cause or contribute to such
differences include, bus are not limited to, continued acceptance of the
Company's products and services in the marketplace, competitive factors, changes
in the regulatory environment, and other risks detailed in the Company's
periodic report filings with the Securities and Exchange Commission. The
statements in this report are made as of today, based upon information currently
known to management, and the Company does not undertake any obligation to
publicly update or revise any forward-looking statements.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
CORGENIX MEDICAL CORPORATION
Date: December 13, 2005 By: /s/ Douglass T. Simpson
---------------------------------
Douglass T. Simpson, President and
Chief Executive Officer
EXHIBIT 99.1
Slide 1:
Agenda:
- -Review of Corporate Goals
- -Product Strategies
- -Review of Fiscal Year 2005 Results
- -Financial Results
- -Achievements and Disappointments
- -Fiscal Year 2006 Plan
- -Plan for 2007-2010
Slide 2:
Corporate Goals:
- -Financial Strength
- -Consistent Growth in Revenues and Profitability
- -Shareholder Liquidity
- -Product Quality
Slide 3:
Product Strategies:
- -Base business
- -Hyaluronic Acid
- -Antiphospholipids
- -Vascular Diseases
- -Autoimmune
- -Growth Opportunities
- -Hyaluronic Acid
- -AtherOx (Ox LDL - B2GP1)
- -Aspirin Resistance
- -Fibromyalgia (chronic pain syndrome)
- -Arenaviruses ELISA
Slide 4:
Strategic Alliances
Slide 5:
FY 2005 Financial Performance:
- --------------------------------------------------------------------------------
Fiscal Year Ended Fiscal Year Ended
6/30/05 6/30/04
audited audited
- --------------------------------------------------------------------------------
- --------------------------------------------------------------------------------
Sales $5,565 $5,271
- --------------------------------------------------------------------------------
- --------------------------------------------------------------------------------
Gross Profit $3,520 $3,397
- --------------------------------------------------------------------------------
- --------------------------------------------------------------------------------
Operating Income $124 $43
- --------------------------------------------------------------------------------
- --------------------------------------------------------------------------------
Net Loss $(582) $(125)
- --------------------------------------------------------------------------------
- --------------------------------------------------------------------------------
EBITDA $268 $240
- --------------------------------------------------------------------------------
Slide 6:
Balance Sheet Highlights
- --------------------------------------------------------------------------------
At June 30, 2005 At June 30, 2004
(audited) (audited)
- --------------------------------------------------------------------------------
- --------------------------------------------------------------------------------
Cash $1,282 $469
- --------------------------------------------------------------------------------
- --------------------------------------------------------------------------------
Working Capital $2,407 $739
- --------------------------------------------------------------------------------
- --------------------------------------------------------------------------------
Stockholder's Equity $2,459 $588
- --------------------------------------------------------------------------------
Slide 7:
FY 2005
- -Accomplishments
- -Revenue growth exceeded industry average
- -Launched AtherOx program
- -Major advancement in several important strategic programs
- -Expanded US and international distribution network
- -Closed institutional financing; restructured
debt
- -Strengthened management team -Reached level of positive operating income
- -Ended the year stronger financially
- -Disappointments
- -Hyaluronic acid product not yet FDA approved
Slide 8:
FY 2006 Goals
- -Continue revenue growth at accelerated rate
- -Demonstrate meaningful progress towards a strategic acquisition
- -Continue improvement in operating income, EBITDA and overall financial strength
- -Move into larger manufacturing facilities providing increased efficiencies
- -Launch several important strategic products
- -Move stock price and trading volumes to the next level
Slide 9:
FY 2006 Performance to Date
- -1st Quarter results
- -Revenues up 26% over prior year
- -Positive operating income
- -Significant increase in stock trading volume
- -NIH grant awarded
- -On track for another record year in terms of sales and EBITDA
Slide 10:
FY 2006 1st Quarter Results
- --------------------------------------------------------------------------------
Fiscal Quarter Ended Fiscal Quarter Ended
9/30/05 9/30/04
(unaudited) (unaudited)
- --------------------------------------------------------------------------------
- --------------------------------------------------------------------------------
Sales $1,635 $1,303
- --------------------------------------------------------------------------------
- --------------------------------------------------------------------------------
Gross Profit $1,053 $746
- --------------------------------------------------------------------------------
- --------------------------------------------------------------------------------
Operating Income (loss) $214 $(86)
- --------------------------------------------------------------------------------
- --------------------------------------------------------------------------------
Net Loss $(124) $(190)
- --------------------------------------------------------------------------------
- --------------------------------------------------------------------------------
EBITDA $261 $(40)
- --------------------------------------------------------------------------------
- --------------------------------------------------------------------------------
At Sept 30, 2005 At Sept. 30, 2004
Slide 11: (unaudited) (unaudited)
Balance Sheet Highlights -
Q1
- --------------------------------------------------------------------------------
- --------------------------------------------------------------------------------
Cash $1,103 $427
- --------------------------------------------------------------------------------
- --------------------------------------------------------------------------------
Working Capital $2,377 $542
- --------------------------------------------------------------------------------
- --------------------------------------------------------------------------------
Stockholder's Equity $2,353 $381
- --------------------------------------------------------------------------------
Slide 12:
Plan for 2007-2010
- -Continue double-digit revenue growth
- -Achieve positive net income
- -Move to listed exchange
- -Drive significantly enhanced shareholder value
- -Build on strategic partnerships
- -Expand business through strategic acquisitions
- -Maintain superior quality system to ensure full regulatory compliance